Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Linda N, Liu"'
Autor:
Gehua Zhen, Yang Dan, Ruomei Wang, Ce Dou, Qiaoyue Guo, Melissa Zarr, Linda N. Liu, Lieping Chen, Ruoxian Deng, Yusheng Li, Zengwu Shao, Xu Cao
Publikováno v:
Bone Research, Vol 9, Iss 1, Pp 1-11 (2021)
Abstract Osteoporosis (OP) is a common age-related disease characterized by a deterioration of bone mass and structure that predisposes patients to fragility fractures. Pharmaceutical therapies that promote anabolic bone formation in OP patients and
Externí odkaz:
https://doaj.org/article/a8554920a26d4080a2d68a5e92d3aeba
Autor:
Saba Shafi, Thazin Nwe Aung, Vasiliki Xirou, Niki Gavrielatou, Ioannis A. Vathiotis, Aileen Fernandez, Myrto Moutafi, Vesal Yaghoobi, Roy S. Herbst, Linda N. Liu, Sol Langermann, David L. Rimm
Publikováno v:
Laboratory Investigation. 102:1143-1149
Immune checkpoint blockade with programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has resulted in significant progress in the treatment of various cancer types. However, not all patients respond to PD-1/PD-L1 blockade, undersc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7c3bd9215e2bbc7154105915ebcba3
https://doi.org/10.1038/s41374-022-00796-6
https://doi.org/10.1038/s41374-022-00796-6
Autor:
Saba Shafi, Thazin Nwe Aung, Charles Robbins, Jon Zugazagoitia, Ioannis Vathiotis, Niki Gavrielatou, Vesal Yaghoobi, Aileen Fernandez, Shuqiong Niu, Linda N. Liu, Zachary T. Cusumano, Nalin Leelatian, Kimberley Cole, He Wang, Robert Homer, Roy S. Herbst, Sol Langermann, David L. Rimm
Publikováno v:
Laboratory Investigation. 102:771-778
Siglec-15, a member of sialic-acid binding immunoglobulin type lectins, is normally expressed by myeloid cells and upregulated in some human cancers and represents a promising new target for immunotherapy. While PD-L1 blockade is an important strateg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcee68d60e7f182b510c1c7d1636b22
https://doi.org/10.1038/s41374-022-00785-9
https://doi.org/10.1038/s41374-022-00785-9
Autor:
Phillip A. Dennis, Joell J. Gills, Linda N. Liu, Sheng Yao, Janis M. Taube, Shigeru Kawabata, Hiroshi Kitagawa, Sharon R. Ghazarian, Haiying Xu, Jeffrey Norris, Qing Kay Li, Willie Wilson, Kristin J. Lastwika
Supplementary Table and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::688a23ebfffbba033ea9b815b8c4ce07
https://doi.org/10.1158/0008-5472.22409163
https://doi.org/10.1158/0008-5472.22409163
Autor:
Phillip A. Dennis, Joell J. Gills, Linda N. Liu, Sheng Yao, Janis M. Taube, Shigeru Kawabata, Hiroshi Kitagawa, Sharon R. Ghazarian, Haiying Xu, Jeffrey Norris, Qing Kay Li, Willie Wilson, Kristin J. Lastwika
Supplemental Table 1. Clinical and pathologic characteristics of patients included in tissue microarrays Supplementary Figure 1. B7-H4 expression is low in human and mouse lung cancer cell lines in vitro Supplementary Figure 2. B7-H1 expression does
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d86c9bd9af6154eead4acb10688f9f8
https://doi.org/10.1158/0008-5472.22409160.v1
https://doi.org/10.1158/0008-5472.22409160.v1
Autor:
Phillip A. Dennis, Joell J. Gills, Linda N. Liu, Sheng Yao, Janis M. Taube, Shigeru Kawabata, Hiroshi Kitagawa, Sharon R. Ghazarian, Haiying Xu, Jeffrey Norris, Qing Kay Li, Willie Wilson, Kristin J. Lastwika
Alterations in EGFR, KRAS, and ALK are oncogenic drivers in lung cancer, but how oncogenic signaling influences immunity in the tumor microenvironment is just beginning to be understood. Immunosuppression likely contributes to lung cancer, because dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b8506aa2c292e7d029766c50ae6962
https://doi.org/10.1158/0008-5472.c.6507711.v1
https://doi.org/10.1158/0008-5472.c.6507711.v1
Autor:
Ce Dou, Ruoxian Deng, Melissa Zarr, Xu Cao, Zengwu Shao, Gehua Zhen, Lieping Chen, Linda N. Liu, Yang Dan, Yusheng Li, Ruomei Wang, Qiaoyue Guo
Publikováno v:
Bone Research, Vol 9, Iss 1, Pp 1-11 (2021)
Bone Research
Bone Research
Osteoporosis (OP) is a common age-related disease characterized by a deterioration of bone mass and structure that predisposes patients to fragility fractures. Pharmaceutical therapies that promote anabolic bone formation in OP patients and OP-induce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a1d509ac4118ac1f7549ecb53f60c5
https://doaj.org/article/a8554920a26d4080a2d68a5e92d3aeba
https://doaj.org/article/a8554920a26d4080a2d68a5e92d3aeba
Autor:
Jun Wang, Miguel F. Sanmamed, Agedi Boto, Kristina A. Archer, Maria I. Toki, Xue Han, Xu Zhou, Solomon Langermann, David L. Rimm, Xinxin Nie, Melissa Zarr, Lieping Chen, Roy S. Herbst, Thomas O'Neill, Jingwei Sun, Linda N. Liu, Dallas B. Flies, Chang Song, Jian-Ping Zhang
Publikováno v:
Nature medicine
Overexpression of the B7-H1 (PD-L1) molecule in the tumor microenvironment (TME) is a major immune evasion mechanism in some patients with cancer, and antibody blockade of the B7-H1/PD-1 interaction can normalize compromised immunity without excessiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f8857aa39b74b69383e6f6e9290734
https://doi.org/10.1038/s41591-019-0374-x
https://doi.org/10.1038/s41591-019-0374-x
Siglec-15 Is a Novel Immunomodulatory Protein and Therapeutic Target in Acute Lymphoblastic Leukemia
Autor:
Sunita I. Park, Christopher C. Porter, Claire E. Pillsbury, Jodi Dougan, Jairo Andres Fonseca, Gloria Gonzalez-Flamenco, Linda N. Liu, Hasan Abukharma
Publikováno v:
Blood. 138:515-515
Immunotherapies have recently shown efficacy in treatment of aggressive, refractory pediatric B cell acute lymphoblastic leukemia (B-ALL), which remains one of the leading causes of cancer-related death in children. The immune evasion mechanisms of B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bf93000277f1c9531f8de69ff0c51b3
https://doi.org/10.1182/blood-2021-153647
https://doi.org/10.1182/blood-2021-153647
Autor:
Shashank Patel, Ana Paucarmayta, Junshik Hong, Ron Copeland, Karla Maloveste, Tae Kon Kim, Carly Hedgepath, Rustin Lovewell, Linda N. Liu, Han Myint, Linjie Tian, Kwang Woon Kim, Thomas O'Neill, Dallas B. Flies, Solomon Langermann
Publikováno v:
Blood. 138:3413-3413
Extensive research has led to recent approval of novel therapies such as mylotarg, venetoclax, glasdegib and CC486, and small molecule inhibitors against actionable mutations such as ivosidenib (IDH1), enasidenib (IDH2), gliteritinib and midostaurin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0dbdd02ad2f5a1a1f00b3443d5969bd8
https://doi.org/10.1182/blood-2021-147656
https://doi.org/10.1182/blood-2021-147656